289 related articles for article (PubMed ID: 28618307)
1. Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
Costa R; Costa RB; Talamantes SM; Helenowski I; Peterson J; Kaplan J; Carneiro BA; Giles FJ; Gradishar WJ
Breast; 2017 Oct; 35():1-7. PubMed ID: 28618307
[TBL] [Abstract][Full Text] [Related]
2. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
Onesti CE; Jerusalem G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):283-298. PubMed ID: 33233970
[No Abstract] [Full Text] [Related]
5. Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
Bøttcher TM; Cold S; Jensen AB
Acta Oncol; 2019 Feb; 58(2):147-153. PubMed ID: 30375908
[TBL] [Abstract][Full Text] [Related]
6. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
7. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity.
Ippolito E; Greco C; Silipigni S; Dell'Aquila E; Petrianni GM; Tonini G; Fiore M; D'Angelillo RM; Ramella S
Breast; 2019 Aug; 46():70-74. PubMed ID: 31100573
[TBL] [Abstract][Full Text] [Related]
8. CDK4-6 inhibitors in breast cancer: current status and future development.
Choo JR; Lee SC
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice.
Rath S; Elamarthi P; Parab P; Gulia S; Nandhana R; Mokal S; Kembhavi Y; Perumal P; Bajpai J; Ghosh J; Gupta S
PLoS One; 2021; 16(7):e0253722. PubMed ID: 34292933
[TBL] [Abstract][Full Text] [Related]
11. Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications.
Santoni M; Occhipinti G; Romagnoli E; Miccini F; Scoccia L; Giulietti M; Principato G; Saladino T; Piva F; Battelli N
BioDrugs; 2019 Dec; 33(6):613-620. PubMed ID: 31529317
[TBL] [Abstract][Full Text] [Related]
12. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Farhat F; Tarabaih M; Kanj A; Aoun M; Kattan J; Assi T; Awada A
Anticancer Drugs; 2020 Jan; 31(1):85-89. PubMed ID: 31609762
[TBL] [Abstract][Full Text] [Related]
14. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Zangardi ML; Spring LM; Blouin GC; Bardia A
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Petrelli F; Ghidini A; Pedersini R; Cabiddu M; Borgonovo K; Parati MC; Ghilardi M; Amoroso V; Berruti A; Barni S
Breast Cancer Res Treat; 2019 Apr; 174(3):597-604. PubMed ID: 30659432
[TBL] [Abstract][Full Text] [Related]
16. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK
Breast Cancer Res Treat; 2019 Feb; 174(1):271-278. PubMed ID: 30465154
[TBL] [Abstract][Full Text] [Related]
17. Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology.
Thibault S; Hu W; Hirakawa B; Kalabat D; Franks T; Sung T; Khoh-Reiter S; Lu S; Finkelstein M; Jessen B; Sacaan A
Mol Cancer Ther; 2019 Feb; 18(2):257-266. PubMed ID: 30401694
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
19. Can CDK4/6 inhibitors cause fatal lung injury?
Jazieh KA; Budd GT; Dalpiaz N; Abraham J
Expert Rev Anticancer Ther; 2019 Nov; 19(11):917-919. PubMed ID: 31566017
[No Abstract] [Full Text] [Related]
20. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
